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Mucolipin 1 (MLN1), also known as TRPML1, is a member of the mucolipin family. The mucolipins are the only lysosomal proteins within
the TRP superfamily. Mutations in the gene coding for TRPML1 result in a lysosomal storage disorder (LSD). This review summarizes the current
knowledge related to this protein and the rest of the mucolipin family.
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TRPMLs are encoded by the MCOLN genes. TRPML1 is
encoded by MCOLN1 localized in humans at chromosome
19p13.2–13.3 while the 2 other genes—MCOLN2 and
MCOLN3 are localized at chromosome 1p22.3 encoding
TRPML2 and TRPML3 respectively. MCOLN1 is mutated in
humans in a lysosomal storage disorder—Mucolipidosis type
IV (MLIV) (MIM #252650), an autosomal recessive, neurode-
generative disease characterized by severe psychomotor
retardation and vision impairment due to retinal degeneration
and cornea opacity (Reviewed by [1–3]). Achlorhydria and iron
deficiency are also part of the clinical symptoms [4,5]. Unlike
most other lysosomal disorders MLIV progresses extremely
slowly, thus patient ages range from 1 year to the late thirties
and forties and life expectancy is not clear yet. Milder patients,
particularly in the psychomotor impairment, were also reported
[6–8].
MLIV is found in increased frequency among Ashkenazi
Jews (AJ) with a heterozygote frequency of 1:100 [9,10]. Over
15 mutations were identified in MLIV patients, Jews and non-
Jews, including two MCOLN1 founder mutations in the AJ
population comprising 95% of the mutated alleles among AJ⁎ Corresponding author. Department of Human Genetics, Hadassah Medical
Center, Jerusaslem 91120, Israel. Fax: +1 972 2 6777499.
E-mail address: Bach@hadassah.org.il (G. Bach).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.01.004MLIV patients [3]. These founder mutations date approximately
40 generation ago [11].
The identification of MCOLN1 mutations opened the door
for accurate patient diagnosis as well as prenatal diagnosis and
heterozygote identification. Lately MLIV is included in the
population screening program operated in various countries
with high concentrations of AJ in an attempt to ascertain high
risk couples, in which both parents are heterozygotes and offer
them options for family planning (prenatal diagnosis, marriage
decisions), as a preventative program to reduce the number of
newly born MLIV patients in the high risk population [12].
1.1. Lysosomal storage
MLIV is classified as a mucolipidosis due to the simulta-
neous lysosomal accumulation of lipids together with water
soluble substances [13]. This characteristic heterogeneous
storage is observed in cells of every tissue and organ of
MLIV patients and principally best demonstrated by electron
microscopy [14–18]. The storage material in MLIV is
autofluorescent [19]. This typical finding is also present in
cultured amniotic fluid cells obtained from MLIV affected
fetuses and thus this technique was used for prenatal diagnosis
purposes in the era preceding the gene discovery [20,21].
Chemical analysis led to the identification of the stored
substances as a variety of lipids namely, gangliosides,
phospholipids and neutral lipids while the water soluble
materials included primarily mucopolysaccharides and glyco-
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sides were predominately stored in neural tissues while
phospholipids were mostly accumulating in visceral organs
[22]. It should be noted that despite the early onset of the disease
in early infancy and the clear evidence of the characteristic
lysosomal storage in these early ages, the fact that the disease
remains in an apparent steady state or very slow deterioration
for at least 2–3 decades may suggest that the storage is not as
massive and progressive as is found in most other lysosomal
storage disorders.
What leads to the storage in MLIV? Earlier studies indicated
that the heterogeneous storage does not stem from the
impairment or deficiency of a lysosomal hydrolase that could
account for this phenomenon [23]. Studies in cultured
fibroblasts with radiolabeled compounds such as phosphatidyl-
choline or gangliosides, which constitute the bulk of the storage
in MLIV, or with fluorescent lipid analogs, indicated that the
abnormal accumulation results from a defect in the late stages of
the endocytosis process of membrane compounds leading to the
impairment of lysosomal biogenesis or, alternatively, a defect in
the normal maintenance of the mature lysosomes [23–26]. It
should be pointed out that another LSD, namely, Niemann–Pick
disease type C (NPC) (MIM #257220) [27] is also suggested to
be involved in defective vesicular trafficking of late endosomes,
although with different cellular and biochemical characteristics
[28–30], thus, these two disorders (MLIVand NPC) constitute a
distinct group within the LSD of endosomal/lysosomal
trafficking impairment leading to defective lysosomal biogen-
esis or function.
Catabolism of the accumulated materials in MLIV still does
occur in the storage vacuoles (early lysosomes? Multivesicular
bodies?) of MLIV patients, though in an altered rate and pattern
(for instance; degradation products are not exported normally
from these organelles to the Golgi apparatus) [24,26]. This helps
to explain the clinical manifestations of this disease, as outlined
above; since despite the early onset of the disease and severe
neurological involvement, MLIV patients remain in an apparent
steady state for decades. This may indicate that indeed the
slower catabolism rate prevents a massive storage as is the case
in most other LSD, and hence, the extremely slow progression
of the clinical picture in these patients.
1.2. Genetics
The gene MCOLN1 was identified by linkage studies
[31–33] following its mapping to human chromosome
19p13.2–13.3 [34]. The identification of this gene triggered
the identification of two other homologous genes, namely,
MCOLN2 and MCOLN3, which mapped to chromosome
1p22.3. The MCOLN genes code for TRPML proteins that
show about 60% amino acid homology to each other. The
identification of the human genes lead to the identification of
similar genes in mice, C. elegans and Drosophila. Over 15
different MCOLN1 mutations have been identified in MLIV
patients, including, partial gene deletions, insertions, splicing,
missense and nonsense mutations [3]. It should be noted that
most missense mutations are located in the putative transmem-brane domains. The clinical severity among the various patients
is very similar regardless the nature of the mutations; but one in-
frame deletion mutation of amino-acid No. 408—phenylala-
nine, is found in a mild patient in compound heterozygosity
with a splicing mutation [3]. Except for AJ, MLIV is considered
to be rare in other populations.
Unlike MCOLN1 there are no reports associating MCOLN2
or MCOLN3 with human diseases. Nevertheless, spontaneous
mutations in MCOLN3 in Varitint–Waddler mice were shown
to be associated with early deafness, vestibula defects, pig-
mentation abnormality and perinatal lethality [35]. At present
no human counterpart was reported. Mutations in a mucolipin-
like gene in C. elegans — CUP5 was reported to be associated
with general lysosomal storage phenomena of a similar nature
as is present in cells of MLIV patients, as well as increased cell
death leading to embryonic lethality [36,37]. Recent reports
have linked the embryonic lethality in CUP5-null C. elegans to
starvation of embryonic cells and general developmental defects
[38]. These observations were suggested to stem from defective
endocytosis of nutrients and the general accumulation of a
genetic suppressor, the ATP-binding cassette (ABC) transporter
MRP-4, in CUP5-null cells [38,39].
Abnormal mitochondrial function due to increased mito-
chondrial fragmentation is observed in MLIV cultured fibro-
blasts, as well as in cell lines from other lysosomal storage
disorders, as a result of inefficient autophagolysosomal
recycling of mitochondria [40]. This leads to decreased Ca2+
buffering capacity in MLIV cells which increases susceptibility
to a caspase-8-dependent apoptotic pathway. This phenomenon
might also explain the increased sensitivity to apoptosis in C.
elegans as described above. The functional link between
mutations in the MCOLN1 gene, mitochondrial aberrations
and the clinical manifestations in MLIV still remains to be seen.
1.3. Mucolipins and subcellular localization
Three proteins are encoded by the MCOLN genes, namely,
TRPML1, TRPML2, and TRPML3 also referred as MLN1–3 or
Mucolipin 1–3, respectively. Following the identification of the
relevant genes the putative structure of the protein products was
deduced by computerized analysis [31]. This indicated that
TRPML1 is 580 amino acids long consisting of 6 transmem-
brane domains which attribute this protein to the TRP
superfamily [41,42], although it does not contain ankirin
domains. The two other TRPML proteins have similar structure.
The physiological function of the mucolipins has not yet
been fully elucidated, but electrophysiological analyses indicate
that they function as cation channels. This was particularly
demonstrated in TRPML1 channels. Based on previous findings
(see above) it is expected that TRPML1 function would be
related to the biogenesis of lysosomes or their normal main-
tenance. Indeed, studies with expression vectors and immuno-
histochemistry demonstrated that TRPML1 is located to
lysosomal vacuoles [26,43–47].
Site directed mutagenesis indicated the role of two dileucine
motifs, one at the N-terminal and the second at the C-terminal
tail of TRPML1, as subcellular targeting motives. Experiments
Table 1
Wild type MCOLN1 and mutations
MCOLN1
mutation
Localization Channel
activity
Low
pH
inhibits
channel
activity
High
Ca2
inhibits
channel
activity
Cleavage References
Wild type Lysosome Yes Yes Yes Yes [26,43–47,
59,60]
T232P ER Slight NDa ND No [43,46]
D362Y ER No ND ND No [46,60]
F408del Lysosome Yes No No Yes [43,59,60]b
V446L ERc Yes No No ND [26]c, [59,60]
F465L Lysosome No ND ND Yes [26,43,46]b
a No data.
b Zeevi, D.A., Frumkin, A, and Bach, G., unpublished data.
c Authors reported unpublished data.
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acids 518–580 fused to the C-terminus of Tac) identified a C-
terminal dileucine motif (amino acids 573–578: EEHSLL) that
represents an AP2-dependent internalization signal responsible
for targeting TRPML1 to early endosomes from the plasma
membrane [44]. In addition, it was found that palmitoylation of
cysteines in close proximity to the C-terminal dileucine motif
(on amino acids 565–567) regulates this endocytotic signaling.
However, the full length TRPML1 protein proved to be
independent of this targeting signal since removal of the C-
terminal dileucine motif was insufficient to mistarget the full
length protein from its proper lysosomal subcellular localization
[26,44–47]. As such, another dileucine motif in the N-terminus
of TRPML1 (consisting of amino acids 11–16: ETERLL) was
identified, containing sufficient lysosomal targeting information
[44,47]. Miedel et al. [45] characterized the trafficking of
TRPML1 by reporting a strict AP1 dependence for the
lysosomal localization of the full length protein [45]. Thus,
taken together, it appears that the N-terminal dileucine motif is
the primary targeting signal of TRPML1 and it is apparently
also AP1 dependent. A simple AP1 knock-down experiment
with a Tac-TRPML1 N-terminus construct should clarify this
point. Furthermore, it has recently been reported in human
fibroblasts that TRPML1 may play a role in lysosomal
exocytosis [48]. This process is characterized by fusion of
lysosomes with the plasma membrane whereby lysosomal
contents are exocytosed. In such a case, the normally lysosomal
TRPML1 may find itself in the “foreign territory” of the plasma
membrane. Hence, the AP2-dependent C-terminal dileucine
internalization motif may be of critical importance to retrieve
TRPML1 to lysosomes from the plasma membrane following
such an exocytotic event.
The cellular localization of TRPML2 and TRPML3 is less
clear, but a recent study which is confirmed in the present
report, indicates that these proteins together with TRPML1 are
capable of interacting with each other (Fig. 3 and [47]). While
TRPML1 and TRPML2 can each transport independently from
the Golgi to lysosomes, TRPML3 requires one of the other two
for its lysosomal localization. These data suggest that in fact all
the members of the mucolipin family are lysosomal proteins but
this should await further confirmation and characterization.
Nevertheless, these observations imply that transfection studies
leading to overexpression of TRPML3, unlike the other two
TRPML proteins, will not reflect the natural localization of this
protein as it will preclude stoichiometric association of the
excess TRPML3 with the other TRPML members thereby
diverting it from targeting to lysosomes.
The fate of TRPML1 in MLIV patients depends upon the
nature of the mutations in the MCOLN1 gene. Naturally, gross
genetic alterations, such as partial gene deletions or splicing
mutations (both of which are the AJ founder mutations), as well
as insertions or non-sense mutations, will basically lead to the
absence of any functional protein. On the other hand, several
missense mutations were shown to cause the misfolded protein
to be retained in the endoplasmic reticulum, apparently due to
the chaperon “proof reading” system, thereby preventing these
mutant proteins from reaching the lysosome [43,46]. Othermissense mutations do reach the lysosomes, but have been
shown to affect TRPML1 channel activity. Table 1 summarizes
the published data regarding the fate of some of the TRPML1
missense mutations. It should be noted, however, that with the
exception of the mild F408 in-frame deletion, all MLIV
mutations to date cause the same, or similar, severe clinical
manifestations.
1.4. Mucolipin structure and protein interactions
The putative structure of TRPML1 is pictured in Fig. 1.
TRPML1 is palmitoylated on its C terminus at residues 565–
567 [44] (and unpublished results). The suggested function of
this palmitoylation has been described above with regard to
trafficking of the protein.
In addition, TRPML1 is also a glycoprotein with four
putative N-linked glycosylation sites (at amino acid positions
159, 179, 220, and 230) in its long luminal loop between
transmembrane domains 1 and 2. TRPML1's N-linked sugars
are sialylated, at least in part, in the Golgi prior to the protein's
transport to lysosomes [45,46]. Interestingly, the N-glycosyla-
tion sites have been used to map a physical and temporal pattern
of TRPML1 cleavage in its long luminal loop. TRPML1 is
cleaved into two distinct cleavage products resulting from a
directed cleavage of TRPML1 between two glycosylation sites
at amino acid positions 179 and 220, respectively [45]. Kiselyov
et al. [46] further characterized the cleavage site by performing
N-terminal sequencing on the C-terminal cleavage product
yielding a putative cleavage site just upstream of the proline at
amino acid position 201. Both studies observed that the N-
linked sugars on both the N and C-terminal cleavage products
are sialylated, suggesting that the temporal cleavage of
TRPML1 occurs post-ER, in a prelysosomal compartment. In
addition, both studies also reported that each cleavage product
co-immunoprecipitates the other, suggesting that the cleavage
products may remain associated with each other after cleavage.
However, one very important discrepancy was observed
between these two studies as Kiselyov et al. [46] were able to
inhibit cleavage of TRPML1 with cathepsin B protease
inhibitors while Meidel et al. [45] resorted to the broad
Fig. 1. The putative structure of TRPML1.
Fig. 2. Endogenous TRPML1. (A) An extract from HEK 293 cells was probed
with C311UP following 12% SDS-PAGE. The full length endogenous TRPML1
protein (65 kDa) and the C-terminus cleavage product (∼35–40 kDa) are
demarcated with arrows. (B) An extract from HEK 293 cells was probed with
N152UP following 12% SDS-PAGE. The full length endogenous TRPML1
protein (65 kDa) and the N-terminus cleavage product (∼35–40 kDa) are
demarcated with arrows. These data confirm that the endogenous TRPML1
protein is also cleaved in vivo as described elsewhere [46].
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leupeptin, to prevent cleavage. Nonetheless, both studies did
qualify their results by not ruling out the possibility of a number
of different proteases being responsible for the cleavage of the
protein.
The most significant finding, with regard to TRPML1
cleavage, is that the endogenous protein has also been found to
undergo cleavage. In addition, it has also been found that the N
and C-terminal cleavage products are in excess with relation to
the full length protein in HEK 293, human skin fibroblast, and
bovine brain cells ([46] and Fig. 2). This suggests that TRPML1
cleavage may play an important role in regulating the function
of the protein. It has already been proposed that cleavage
inactivates the channel function of TRPML1 [46].
Overexpression of TRPML1 has led to the discovery of two
predominant observations. The first is the distinct possibility of
plasma membrane localization predominating over the widely
agreed upon lysosomal localization of the protein. This
phenomenon was used in HEK 293 cells where plasma
membrane localization facilitates simple electrophysiological
recordings via standard patch-clamp methods [46,49]. None-
theless, all such electrophysiological recordings must be
qualified in light of the fact that the lysosomal membrane is
different, topologically and structurally, from the plasma
membrane. Aside from both membranes featuring different
populations of glycolipids, sphingolipids, and phospholipids;
the lysosomal membrane is also a specialized single lipid
bilayer membrane as opposed to the double lipid bilayer plasmamembrane [50–52]. These and other differences between the
lysosomal membrane and the plasma membrane likely reflect
important influences upon electrophysiological recordings.
The second observation that predominates in TRPML1 but
also TRPML2, and TRPML3 overexpression, is the formation
of indissociable aggregates. These aggregates have appeared in
pictured immunoblots of TRPML1 in a number of different
publications [43–45,53]. We also observed a similar observa-
tion with regard to TRPML2 and TRPML3 (Fig. 3). While
Fig. 3. TRPML1 co-immunoprecipitates TRPML2 and TRPML3. C311UP was
used to immunoprecipitate (IP) and immunoblot (Blot) TRPML1-YFP,
monoclonal anti-HA antibody was used to immunoprecipitate and immunoblot
TRPML2-HA, and monoclonal anti-c-myc antibody was used to immunopre-
cipitate and immunoblot c-Myc-TRPML3. (A) TRPML2-HA co-immunopre-
cipitates TRPML1-YFP (left panel) and TRPML1-YFP co-immunoprecipitates
TRPML2-HA (right panel). “Residual” lanes represent unbound protein
following immunoprecipitation with the indicated antibody. “Lysate” lanes
represent cell lysates not treated with antibodies. Note the upper bands on both
immunoblots representing aggregated forms of these proteins. The monomeric
bands are demarcated with arrows. (B) c-Myc-TRPML3 co-immunoprecipitates
TRPML1-YFP (left panel) and TRPML1-YFP co-immunoprecipitates c-Myc-
TRPML3 (right panel). Note the upper bands on both immunoblots representing
aggregated forms of these proteins. The monomeric bands are demarcated with
arrows.
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verified due to the lack of antibodies that recognize these
endogenous proteins, characterization of the endogenous
TRPML1 has revealed no indissociable aggregates in immuno-
blots carried out on control HEK 293 cells (Fig. 2). It is assumed
that due to the highly hydrophobic nature of the TRPML
integral membrane proteins, aggregation in overexpression
would be unavoidable.
Nevertheless, overexpressed protein aggregation does not
preclude the possibility of protein–protein interactions existing
between the different TRPMLs and each other. One common
feature of many TRP proteins is the ability to homo- and hetero-
multimerize with closely related members of the same
subfamily [54,55]. Indeed, Venkatachalam et al. [47] reported
interactions between TRPML1 and both TRPML2 and
TRPML3, respectively, using a FRET-based approach. This
same approach demonstrated an interaction between TRPML2
and TRPML3 as well. Here we further report that TRPML1 also
co-immunoprecipitates TRPML2 and TRPML3 and vice-versa
(Fig. 3). These protein interactions and others await verification
with controlled experiments on the endogenous TRPMLproteins in the future. Nonetheless, the concept of TRPML1
being part of a complex is important when considering
optimization of future experiments to characterize the structure
and function of the protein. The concept of a complex structure
involving the different mucolipins and the implications for
MLIV awaits further elucidation.
2. TRPML1 channel activity
The mechanism which accounts for the pathogenesis of
MLIV is not clear. The initial assessment of the function of
TRPML1 was suggested by its predicted protein structure [31],
which indicated one transmembrane (TM) helix in the amino-
terminal region and at least five transmembrane domains in the
carboxy-terminal half of the protein (Fig. 1). The putative
structure of six transmembrane domains along with a TRP
cation channel motif spanning the third to the sixth TM domains
suggested that the protein belongs to the TRP superfamily [56]
with a high resemblance to the polycystin-2/TRPP2 protein
[57]. Thus it was expected that TRPML1 function as a cation
channel.
The ability to perform electrophysiological analyses of
channel activity, in order to prove the above assumption, suffers
from serious limitation since the protein is located in the
lysosomal and/or late endosomal membrane. Therefore electro-
physiological recordings have been made possible only after
overexpressing the protein in different cell types in ectopic
locations.
Overexpression of the protein to the Xenopus oocyte plasma
membrane observed TRPML1 as a novel channel with a large
conductance and permeability to Na+, K+ and Ca2+ [58]. An
overexpressed protein which is located in an ectopic location
does not necessarily reflect the endogenous activity of the
channel, especially in an environment where other channel
proteins might interact with the overexpressed protein. Thus, a
different approach to record the channel activity of the
overexpressed protein in a relatively isolated environment was
taken [59]. The channel activity was assessed in endosomal
vesicles of MLIV patient and in TRPML1 over-expressing cells,
as well as in proteoliposomes which contained the in vitro
translated protein [60]. Electrical recordings of the channel from
both preparations indicated that wild type TRPML1 is a
multiple subconductance non-selective cation channel whose
function is inhibited by Ca2+ transport and a reduction of pH
[59,60]. Since it was shown in this system that mutated channels
lost their ability to be regulated by Ca2+ and by lowering pH, it
was suggested that this might hint to the mechanism which
underlies the pathophysiology of the disease. Intravesicular pH
is critical in endosomal/lysosomal fusion, suggesting that its
regulation (possibly by Ca2+) is essential for the ability of
vesicular organelles to fuse [61,62].
In a different approach, the channel conductance was
measured by whole cell current recording after mistargeting
the protein to the plasma membrane in HEK 293 cells. In this
system TRPML1 showed characteristic strong outwardly
rectifying current [46]. Following these recordings a new
mechanism was suggested for the pathogenesis of MLIV.
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as a proton channel and demonstrated a decrease in the
lysosomal pH in cultured cells of MCOLN1 mutants when
compared to normal. This suggests that TRPML1 might
function as a pH regulator of lysosomes, whose function is to
pump H+ ions out of these organelles when this milieu
becomes acidified during the catabolism process. Thus,
TRPML1 functions as a pH regulator in maintaining the
required acidity for the normal activity of lysosomal hydro-
lases. It was also demonstrated that supplying lysosomes with
weak bases lead to the correction of lysosomal storage as
judged by electron microscopy observations. These data
remain to be confirmed and further characterized.
The most recent study of TRPML1 channel activity claims
that none of the above electrophysiological recordings could be
reproduced [26]. This study proves that correct targeting of
TRPML1 to lysosomes and the integrity of its predicted ion
pore are essential for its physiological function. The authors
mention the following reasons to explain the difficulty of
obtaining electrophysiological data from TRPML1 in trans-
fected cells: (1) the channel may be inactivated by proteolytic
cleavage; (2) subunits which might be needed for channel
oligomerization may be missing; and (3) possible TRPML1-
interacting proteins, which could be needed for gating the
channel, may also be missing.
MLIV research has presented with conflicting results well
before the cloning of the MCOLN1 gene. Nowadays, the
conflicting electrophysiological recordings of the overex-
pressed protein are confounded by confusing data with regard
to lysosomal pH of MLIV patient fibroblasts. While we found
elevated pH [63], others reported normal [26,64] or reduced pH
[49]. While the pH discrepancies could be explained by the
autoflourescence of the MLIV fibroblasts, the other conflicting
results could be explained by the artificial conditions of the
mistargted and overexpressed proteins. In their review which
deals with “Cellular and molecular function of mucolipins and
polycystin 2”, Qian and Noben-Trauth [65] mention a variety of
experiments with polycystin 2 that describe its localization at
various intracellular locations. They suggest that these dis-
crepancies could be explained by differing methodologies,
however, they also predict that differing results may stem from
dynamic intracellular trafficking of polycystin-2 and that this
trafficking may display variable regulation in various tissues.
These principles might hold for TRPML1, the closest relative of
polycystin 2, but only further investigation into the dynamic
trafficking of this protein would give a firm support to this idea.
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Appendix A. Materials and methods
A.1. TRPML Expression Constructs
TRPML1-YFP was prepared by cloning MCOLN1 cDNA
(Genbank Accession no.: AF249319) derived from controlhuman skin fibroblasts into the pEYFP-N1 vector (Clontech)
with NheI and BamHI restriction enzymes. This construct fused
YFP to the C-terminus of TRPML1. Myc-TRPML3 was
prepared by cloning the MCOLN3 CDS (Genbank Accession
no.: NM_018298) derived from control human lymphoblastoid
cells into the pCS2+MT vector using EcoRI and XbaI restriction
enzymes. This construct fused six Myc tags to the N-terminus of
TRPML3. TRPML2-HA was prepared by removing the Myc
tags from pCS2+MTwith BamHI and XhoI restriction enzymes.
The MCOLN2 CDS (Genbank Accession no.:BC104893),
derived from control human lymphoblastoid cells, was then
cloned into the BamHI and XhoI restriction sites with an HA-
coding tag (sequence: ATGTACCCATACGATGTTCCAGAT-
TACGCTTAA) appended to the 3′ end of the CDS. All inserts
orientation and polymerase fidelity were verified by restriction
enzyme mapping and sequencing.
A.2. Cell culture and transient transfection
HEK293 cells were maintained in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% fetal calf
serum (FCS) and 100 μg/ml penicillin/streptomycin. Transient
co-transfection was carried out in 100-mm dishes with 3 μg of
total plasmid DNA (1.5 μg of each plasmid), and 9 μl of
FuGENE-6 (Roche Molecular Biochemicals).
A.3. Anti-TRPML1 antibodies
Glutathione-S-Transferase (GST) fusion proteins were gene-
rated by cloning each of the N and C terminal portions of
TRPML1 (corresponding to amino acids 1–70 and 520–576,
respectively) into the bacterial expression vector, PGEX-3X
(Amersham BioSciences), with BamHI and EcoRI restriction
enzymes. These constructs were used to express the N and C
terminal portions of TRPML1 at the carboxyl end of GST in
BL21 bacteria. Each GST fusion protein was subsequently
purified from bacterial lysates with glutathione–agarose
(Amersham BioSciences) and used to immunize New Zealand
White rabbits to generate polyclonal antisera. Antisera N152
was raised against the GST-TRPML1 N terminus fusion protein
and antisera C311 was raised against the GST-TRPML1 C
terminus fusion protein.
Affinity purified antibodies were prepared by synthesizing
small peptides located within the N152 and C311 epitopes on
TRPML1. Peptide NH-CPTPPEEEDLRRRL-COOH, corre-
sponding to TRPML1 amino acids 33–45 with an appended
N terminus cysteine, was used to purify N152; and peptide NH-
CQDSPTSGKFRRGSG-COOH, corresponding to TRPML1
amino acids 544–556, was used to purify C311. These peptides
were each coupled via their N terminus cysteines to SulfoLink
Coupling Gel (Pierce Biotechnology) followed by affinity
purification of the corresponding antisera. The resulting affinity
purified antibodies were called N152UP and C311UP, res-
pectively. The specificity of these antibodies was verified by
recognition of the transfected TRPML1-YFP protein (as
verified by mass spectrometry analysis), by blocking the signal
with the peptides used to affinity purify the specific antibodies
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lymphoblastoid cell extracts.
A.4. Immunoblotting
Cells were solubilized in lysis buffer containing 1% Triton
X-100, 25 mM Tris–HCl (pH 7.5), 150 mM NaCl, 5 mM
EDTA, and complete TM protease inhibitor cocktail (Santa
Cruz). Lysates were diluted in Laemmli sample buffer and
heated to 55 °C prior to SDS-PAGE and immunoblotting with
monoclonal anti-HA (HA-7, Sigma), monoclonal anti-c-Myc
(9E10, Santa Cruz) or anti-TRPML1 antibodies, C311UP/
N152UP. Blots were developed with Western Blotting Luminol
Reagent (Santa Cruz) unless endogenous TRPML1 proteins
were probed, in which case blots were developed with Lumiglo
Reserve Enhanced Chemiluminescence (KPL).
A.5. Immunoprecipitation
Co-transfected HEK 293 lysates were divided into two
separate tubes and immunoprecipitated with monoclonal anti-
HA, monoclonal anti-c-Myc, or C311UP antibodies, as
necessary. Immunocomplexes were recovered at 4 °C overnight
with Protein A/G PLUS-agarose (Santa Cruz). The unbound
protein solution was saved for immunoblotting and the
immunoprecipitate was then washed five times with lysis
buffer followed by a final wash in 50 mM Tris pH 8.
Precipitated proteins were eluted with 2× Laemmli sample
buffer and heated to 55 °C for 5 min prior to 10% SDS-PAGE
and immunoblotting as described above. Prior to co-immuno-
precipitation experiments, it was determined that C311UP does
not cross-react with TRPML2 and TRPML3.
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